A Study of the Relative Bioavailability of ASC41 in Healthy Subjects

• Sponsor: Ascletis Pharmaceuticals Co., Ltd. (Industry)
• Overall Status: Completed
• CT.gov ID: NCT04527250
• Collaborator: Hunan Provincial People's Hospital (Other)
• Enrollment: 60
• Location: 1
• Arms: 10
• Actual Duration (Months): 3.4
• Patients Per Site Per Month: 17.4

Study Details

Study Description

Brief Summary

The objective of this study is to compare the pharmacokinetic parameters of ASC41 in healthy subjects after single and multiple oral dosing.

Condition or Disease	Intervention/Treatment	Phase
Healthy	Drug: ASC41; Drug: ASC41 placebo	Phase 1

Detailed Description

The purpose of this study was to evaluate the tolerability, safety pharmacokinetics and pharmacodynamic (biomarkers) of ASC41 tables in a randomized, double-blind, placebo-controlled single- and multiple-dose phase I clinical trial in healthy subjects the study. The effects of ASC41 on LDL-C and other lipid parameters (TG, TC, HDL-C, etc.) will be observed after repeated administration of ASC41 in healthy subjects.

Study Design

• Study Type: Interventional
• Actual Enrollment: 60 participants
• Allocation: Randomized
• Intervention Model: Parallel Assignment
• Masking: Double (Participant, Care Provider)
• Primary Purpose: Treatment
• Official Title: Comparison of the Pharmacokinetic Parameters of ASC41, a Randomized, Double-blind, Placebo-controlled in Healthy Subjects After Single and Multiple Doses
• Actual Study Start Date: Sep 16, 2020
• Actual Primary Completion Date: Dec 18, 2020
• Actual Study Completion Date: Dec 30, 2020

Arms and Interventions

Arm	Intervention/Treatment
Experimental: Experimental:1mg ASC41 one tablet (1mg) single oral dose at Day 1 and once daily for 14 days from Day 14 to Day 27.	Drug: ASC41; ASC41,1mg/table;5mg/table
Experimental: Experimental:2mg ASC41 two tablets (2mg) single oral dose at Day 1 and two tablets daily for 14 days from Day 14 to Day 27.	Drug: ASC41; ASC41,1mg/table;5mg/table
Experimental: Experimental:5mg ASC41 one tablet (5mg) single oral dose at Day 1 and once daily for 14 days from Day 14 to Day 27.	Drug: ASC41; ASC41,1mg/table;5mg/table
Experimental: Experimental:10mg ASC41 two tablets (10mg) single oral dose at Day 1.	Drug: ASC41; ASC41,1mg/table;5mg/table
Experimental: Experimental:20mg ASC41 four tablets (20mg) single oral dose at Day 1.	Drug: ASC41; ASC41,1mg/table;5mg/table
Placebo Comparator: Placebo:1mg ASC41 placebo one tablet (1mg) single oral dose at Day 1 and once daily for 14 days from Day 14 to Day 27.	Drug: ASC41 placebo; ASC41 placebo,1mg/table;5mg/table
Placebo Comparator: Placebo:2mg ASC41 placebo two tablets (2mg) single oral dose at Day 1 and two tablets daily for 14 days from Day 14 to Day 27.	Drug: ASC41 placebo; ASC41 placebo,1mg/table;5mg/table
Placebo Comparator: Placebo:5mg ASC41 placebo one tablet (5mg) single oral dose at Day 1 and once daily for 14 days from Day 14 to Day 27.	Drug: ASC41 placebo; ASC41 placebo,1mg/table;5mg/table
Placebo Comparator: Placebo:10mg ASC41 placebo two tablets (10mg) single oral dose at Day 1.	Drug: ASC41 placebo; ASC41 placebo,1mg/table;5mg/table
Placebo Comparator: Placebo:20mg ASC41 placebo four tablets (20mg) single oral dose at Day 1.	Drug: ASC41 placebo; ASC41 placebo,1mg/table;5mg/table

Outcome Measures

Primary Outcome Measures

1. Evaluation of the safety and tolerability of ASC41 in healthy volunteers [Up to 32 days]

   Evaluation of the safety and tolerability of ASC41 in healthy volunteers

Secondary Outcome Measures

1. Cmax of ASC41 [On Day 1,2,3,4 after single doses and On Day 1,2,3,4 after multiple doses, respectively. The entire study will last up to 32 days.]

   Evaluate the Peak Plasma Concentration after single and multiple oral doses of ASC41 administered to Chinese healthy volunteers.

2. Tmax of ASC41 [On Day 1,2,3,4 after single doses and On Day 1,2,3,4 after multiple doses, respectively. The entire study will last up to 32 days.]

   Evaluate the Time to reach the maximum plasma concentration after single and multiple oral doses of ASC41 administered to Chinese healthy volunteers.

3. AUC of ASC41 [On Day 1,2,3,4 after single doses and On Day 1,2,3,4 after multiple doses, respectively. The entire study will last up to 32 days.]

   Evaluate the Area under the plasma concentration versus time curve after single and multiple oral doses of ASC41 administered to Chinese healthy volunteers.

4. t1/2 of ASC41 [On Day 1,2,3,4 after single doses and On Day 1,2,3,4 after multiple doses, respectively. The entire study will last up to 32 days.]

   Evaluate the Terminal-Phase Half-Life after single and multiple oral doses of ASC41 administered to Chinese healthy volunteers volunteers.

5. CL/F of ASC41 [On Day 1,2,3,4 after single doses and On Day 1,2,3,4 after multiple doses, respectively. The entire study will last up to 32 days.]

   Evaluate the Apparent Systemic Clearance after single and multiple oral dose of ASC41 administered to Chinese healthy volunteers.

6. Vd/F of ASC41 [On Day 1,2,3,4 after single doses and On Day 1,2,3,4 after multiple doses, respectively. The entire study will last up to 32 days.]

   Evaluate the Apparent Volume of Distribution after single and multiple oral dose of ASC41 administered to Chinese healthy volunteers.

Eligibility Criteria

Criteria

• Ages Eligible for Study: 18 Years to 45 Years
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: Yes

Inclusion Criteria:

• 1. Age 18-45 (including boundary value). 2. Male weight ≥ 50kg, female weight ≥ 45kg;BMI ranges from 19 to 30kg/m2 (boundary value included).

1. She is of childbearing potential and is non-pregnant and willing to use adequate contraception from screening (within 30days from the first administration)until one month after the End of Study visit.

2. The pregnancy test of female subjects during the screening period is negative.

3. During the screening period, fasting low-density lipoprotein cholesterol (110mg/dl < fasting (LDL-C) < 190mg/ dL.

4. Those who voluntarily sign the informed consent.

Exclusion Criteria:

• 1. Patients with a history of thyroid disease or intolerance to beta blockers or abnormal thyroid function indicators during screening; 2. Previous history of fainting, fainting needle or fainting blood for unknown reasons.

1. Previous liver disease, or ALT, ASL and direct bilirubin in screening period exceed the normal range.

2. Hepatitis B surface antigen (HBsAg), Hepatitis C virus antibody (HCV Ab), HIV antibody (HIV Ab) and syphilis antibody are tested positive.

3. People who have taken special diet (including carambola, dragon fruit, mango, grapefruit, orange, etc.) or drunk alcohol, or had strenuous exercise, or other factors affecting drug absorption, distribution, metabolism, and excretion within 2 weeks before taking the study drug.

4. Heavy smokers (14 units of alcohol per week: 1 unit = 285 mL beer, or 25 mL spirits, or 100 mL wine;Smoking daily ≥ 5 sticks) and no smoking or alcohol prohibition during the study period.

5. Ingesting chocolate, any food or drink containing caffeine or xanthine in the 24 hours prior to taking the study drug.

6. Patients who had donated blood or lost blood of more than 400ml within 3 months before taking the study drug.

7. Those who have participated in other clinical trials and received study drug treatment within 3 months before taking study drug.

8. In addition to the above, the researchers judge that the participants are not suitable to participate in this clinical trial.

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	Hunan provincial people's hospital	Changsha	Hunan	China

Sponsors and Collaborators

• Ascletis Pharmaceuticals Co., Ltd.
• Hunan Provincial People's Hospital

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.

• Responsible Party: Ascletis Pharmaceuticals Co., Ltd.
• ClinicalTrials.gov Identifier: NCT04527250
• Other Study ID Numbers: ASC-ASC41-I-CTP-02
• First Posted: Aug 26, 2020
• Last Update Posted: Aug 20, 2021
• Last Verified: Aug 1, 2021

• Individual Participant Data (IPD) Sharing Statement: Undecided
• Plan to Share IPD: Undecided
• Studies a U.S. FDA-regulated Drug Product: No
• Studies a U.S. FDA-regulated Device Product: No

Study Results

No Results Posted as of Aug 20, 2021